{"transactions":[{"id":1045375,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2025-09-09T20:02:56.000Z","date":"2025-09-05","kind":"purchase","planned":false,"acquired":true,"shares":1113,"price":18.8572,"value":20988.0636,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":13027,"source":{"system":"sec-edgar","filing":"0000950170-25-113800","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025113800/ownership.xml","form_type":"4"}},{"id":1218517,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Share Units","published_at":"2025-03-07T21:22:46.000Z","date":"2025-03-05","kind":"grant","planned":false,"acquired":true,"shares":56603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted share units were granted on March 5, 2025, with 14,150 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 14,153 vesting on March 5, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted share units were granted on March 5, 2025, with 14,150 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028, and 14,153 vesting on March 5, 2029."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":56603,"derivative":{"underlying":"Ordinary Shares","underlying_shares":56603},"source":{"system":"sec-edgar","filing":"0000950170-25-035533","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025035533/ownership.xml","form_type":"4"}},{"id":1220825,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Share Units","published_at":"2025-03-06T21:16:53.000Z","date":"2025-03-04","kind":"exercise","planned":true,"acquired":false,"shares":16741,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Restricted share units were granted on March 4, 2024, with 16,741 vested on March 4, 2025, and 16,741 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Restricted share units were granted on March 4, 2024, with 16,741 vested on March 4, 2025, and 16,741 vesting on each of March 4, 2026, March 4, 2027 and March 4, 2028."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":50223,"derivative":{"underlying":"Ordinary Shares","underlying_shares":16741},"source":{"system":"sec-edgar","filing":"0000950170-25-034670","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025034670/ownership.xml","form_type":"4"}},{"id":1220824,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-06T21:16:53.000Z","date":"2025-03-05","kind":"sale","planned":true,"acquired":false,"shares":1677,"price":15.9132,"value":26686.4364,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.68 to $16.13, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":11914,"source":{"system":"sec-edgar","filing":"0000950170-25-034670","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025034670/ownership.xml","form_type":"4"}},{"id":1220823,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-06T21:16:53.000Z","date":"2025-03-04","kind":"sale","planned":true,"acquired":false,"shares":3150,"price":15.7346,"value":49563.99,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024."},{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $16.015, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":13591,"source":{"system":"sec-edgar","filing":"0000950170-25-034670","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025034670/ownership.xml","form_type":"4"}},{"id":1220822,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-06T21:16:53.000Z","date":"2025-03-04","kind":"exercise","planned":true,"acquired":true,"shares":16741,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":16741,"source":{"system":"sec-edgar","filing":"0000950170-25-034670","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025034670/ownership.xml","form_type":"4"}},{"id":1600211,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Legal Officer"}}],"security":"Restricted Share Units","published_at":"2024-03-05T21:46:42.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":66964,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted share units were granted on March 4, 2024, with 16,741 vesting on each of March 4, 2025, March 4, 2026, March 4, 2027 and March 4, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted share units were granted on March 4, 2024, with 16,741 vesting on each of March 4, 2025, March 4, 2026, March 4, 2027 and March 4, 2028."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":66964,"derivative":{"underlying":"Ordinary Shares","underlying_shares":66964},"source":{"system":"sec-edgar","filing":"0000950170-24-026140","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017024026140/ownership.xml","form_type":"4"}},{"id":1766066,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Gen Counsel, CCO, & Secretary"}}],"security":"Restricted Stock Units","published_at":"2023-10-04T21:40:24.000Z","date":"2023-10-02","kind":"exercise","planned":false,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit converted into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The restricted stock units vested in full on October 2, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The restricted stock units vested in full on October 2, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001628280-23-033914","document":"wk-form4_1696470013.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/819050/000162828023033914/wk-form4_1696470013.xml","form_type":"4"}},{"id":1766065,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Gen Counsel, CCO, & Secretary"}}],"security":"Common Stock","published_at":"2023-10-04T21:40:24.000Z","date":"2023-10-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":7358,"price":0.9798,"value":7209.3684,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares withheld by the issuer to satisfy tax withholding obligations upon the vesting of restricted stock units."}],"balance_after":16061,"source":{"system":"sec-edgar","filing":"0001628280-23-033914","document":"wk-form4_1696470013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/819050/000162828023033914/wk-form4_1696470013.xml","form_type":"4"}},{"id":1766064,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Gen Counsel, CCO, & Secretary"}}],"security":"Common Stock","published_at":"2023-10-04T21:40:24.000Z","date":"2023-10-02","kind":"exercise","planned":false,"acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units were granted on January 24, 2023 and were subject to accelerated vesting as of the date of the reporting person's termination pursuant to his employment agreement with the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit converted into common stock on a one-for-one basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This balance includes 555 shares purchased under the Fresh Tracks Therapeutics, Inc. Employee Stock Purchase Plan that were not previously reported."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"On July 5, 2022, the registrant effected a 1-for-45 reverse stock split (\"Reverse Stock Split\") of its common stock. The number of shares beneficially owned has been adjusted to give effect to the Reverse Stock Split."}],"balance_after":23419,"source":{"system":"sec-edgar","filing":"0001628280-23-033914","document":"wk-form4_1696470013.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/819050/000162828023033914/wk-form4_1696470013.xml","form_type":"4"}},{"id":2045667,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Gen Counsel, CCO, & Secretary"}}],"security":"Restricted Stock Units","published_at":"2023-01-26T18:49:42.000Z","date":"2023-01-24","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of issuer common stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in full on the first anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in full on the first anniversary of the grant date."}],"balance_after":20000,"derivative":{"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000819050-23-000008","document":"wf-form4_167477696231987.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/819050/000081905023000008/wf-form4_167477696231987.xml","form_type":"4"}},{"id":2278536,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-09T16:17:50.000Z","date":"2022-05-05","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest 25% on the first anniversary of the grant date, and the remainder will vest in equal monthly installments over the following three years."}],"balance_after":300000,"derivative":{"exercise_price":0.26,"exercise_date":"2023-05-05","expiration_date":"2032-05-05","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000819050-22-000049","document":"wf-form4_165212745351640.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/819050/000081905022000049/wf-form4_165212745351640.xml","form_type":"4"}},{"id":2624456,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Common Stock","published_at":"2021-07-27T16:42:16.000Z","date":"2021-07-23","kind":"purchase","acquired":true,"shares":18124,"price":0.6697,"value":12137.6428,"ownership":{"direct":true},"balance_after":128879,"source":{"system":"sec-edgar","filing":"0000819050-21-000124","document":"wf-form4_162741845824709.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/819050/000081905021000124/wf-form4_162741845824709.xml","form_type":"4"}},{"id":2670952,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-14T16:43:57.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest 25% on June 14, 2022, and the remainder will vest in equal monthly installments over the following three years."}],"balance_after":200000,"derivative":{"exercise_price":0.9,"exercise_date":"2022-06-14","expiration_date":"2031-06-14","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000819050-21-000085","document":"wf-form4_162370341305839.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/819050/000081905021000085/wf-form4_162370341305839.xml","form_type":"4"}},{"id":2706583,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Common Stock","published_at":"2021-05-19T17:02:26.000Z","date":"2021-05-17","kind":"purchase","acquired":true,"shares":7980,"price":0.8,"value":6384.0,"ownership":{"direct":false,"nature":"By Spouse"},"balance_after":13980,"source":{"system":"sec-edgar","filing":"0001062993-21-004867","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299321004867/form4.xml","form_type":"4"}},{"id":2706582,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Common Stock","published_at":"2021-05-19T17:02:26.000Z","date":"2021-05-17","kind":"purchase","acquired":true,"shares":18622,"price":0.8,"value":14897.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the purchase of 18,622 shares in multiple transactions, ranging in price from $0.7942 to $0.8097 per share, resulting in a weighted average purchase price of $0.806. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each price within the range."}],"balance_after":110755,"source":{"system":"sec-edgar","filing":"0001062993-21-004867","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299321004867/form4.xml","form_type":"4"}},{"id":2784336,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Restricted Stock Units","published_at":"2021-03-17T16:53:18.000Z","date":"2021-03-16","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\") converted into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs vested in full on March 16, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These RSUs vested in full on March 16, 2021."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001062993-21-002790","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299321002790/form4.xml","form_type":"4"}},{"id":2784335,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Common Stock","published_at":"2021-03-17T16:53:18.000Z","date":"2021-03-16","kind":"tax_withholding","acquired":false,"shares":8750,"price":1.14,"value":9975.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy tax withholding obligations upon the vesting of RSUs."}],"balance_after":92133,"source":{"system":"sec-edgar","filing":"0001062993-21-002790","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299321002790/form4.xml","form_type":"4"}},{"id":2784334,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Common Stock","published_at":"2021-03-17T16:53:18.000Z","date":"2021-03-16","kind":"exercise","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\") converted into common stock on a one-for-one basis."}],"balance_after":100883,"source":{"system":"sec-edgar","filing":"0001062993-21-002790","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299321002790/form4.xml","form_type":"4"}},{"id":3026388,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Common Stock","published_at":"2020-09-21T16:19:28.000Z","date":"2020-09-18","kind":"purchase","acquired":true,"shares":6000,"price":0.8398,"value":5038.8,"ownership":{"direct":false,"nature":"By spouse"},"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001062993-20-004584","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299320004584/form4.xml","form_type":"4"}},{"id":3026387,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Common Stock","published_at":"2020-09-21T16:19:28.000Z","date":"2020-09-18","kind":"purchase","acquired":true,"shares":16526,"price":0.8298,"value":13713.2748,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the purchase of 16,526 shares in multiple transactions, ranging in price from $0.8224 to $0.8429 per share, resulting in a weighted average purchase price of $0.8298. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each price within the range."}],"balance_after":75883,"source":{"system":"sec-edgar","filing":"0001062993-20-004584","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299320004584/form4.xml","form_type":"4"}},{"id":3029362,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Stock Option (right to buy)","published_at":"2020-09-17T17:05:40.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options will vest 25% on September 15, 2021, and the remainder will vest in equal monthly installments over the following three years."}],"balance_after":350000,"derivative":{"exercise_price":0.8,"expiration_date":"2030-09-15","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001062993-20-004553","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/819050/000106299320004553/form4.xml","form_type":"4"}},{"id":3103605,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Common Stock Warrants (right to buy)","published_at":"2020-06-22T19:52:24.000Z","date":"2020-06-22","kind":"purchase","acquired":true,"shares":30435,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased by the reporting person at a combined public offering price of $1.15 per share of common stock and accompanying warrant exercisable for one share of common stock."}],"balance_after":30435,"derivative":{"exercise_price":1.25,"exercise_date":"2020-06-22","expiration_date":"2025-06-22","underlying":"Common Stock","underlying_shares":30435},"source":{"system":"sec-edgar","filing":"0000911916-20-000136","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/819050/000091191620000136/edgar.xml","form_type":"4"}},{"id":3103604,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Common Stock","published_at":"2020-06-22T19:52:24.000Z","date":"2020-06-22","kind":"purchase","acquired":true,"shares":30435,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were purchased by the reporting person at a combined public offering price of $1.15 per share of common stock and accompanying warrant exercisable for one share of common stock."}],"balance_after":59357,"source":{"system":"sec-edgar","filing":"0000911916-20-000136","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/819050/000091191620000136/edgar.xml","form_type":"4"}},{"id":3203599,"issuer":{"id":90076,"kind":"organization","name":"Fresh Tracks Therapeutics, Inc.","symbol":"FRTX"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel and CCO"}}],"security":"Restricted Stock Units","published_at":"2020-03-18T16:30:21.000Z","date":"2020-03-16","kind":"grant","acquired":true,"shares":25000,"price":1.54,"value":38500.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":1.54,"exercise_date":"2021-03-16","expiration_date":"2030-03-15","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001214659-20-002729","document":"marketforms-48377.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/819050/000121465920002729/marketforms-48377.xml","form_type":"4"}},{"id":3721075,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2018-12-21T12:53:49.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":37500,"price":21.04,"value":789000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 5, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This Company stock option was scheduled to vest 1/4 annually over a period of 4 years beginning on February 5, 2019. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":2.96,"expiration_date":"2028-01-05","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001104659-18-074358","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074358/a4.xml","form_type":"4"}},{"id":3721074,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2018-12-21T12:53:49.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":23750,"price":24,"value":570000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This restricted stock unit (\"RSU\") award provided for vesting and settlement 1/4 annually over a period of 4 years beginning on February 5, 2019 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-074358","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074358/a4.xml","form_type":"4"}},{"id":3721073,"issuer":{"id":161591,"kind":"organization","name":"ENDOCYTE INC","symbol":"ECYT"},"owners":[{"id":75635,"kind":"person","name":"McAvoy David R.","position":1,"cik":"0001758842","reported_name":"McAvoy David R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2018-12-21T12:53:49.000Z","date":"2018-12-21","kind":"disposition_to_issuer","acquired":false,"shares":2119,"price":24,"value":50856.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 1,684 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on December 14, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the \"Merger Agreement\"), by and among Endocyte, Inc. (the \"Company\"), Novartis AG (\"Novartis\") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis (\"Merger Sub\"), at the effective time (the \"Effective Time\") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-074358","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235007/000110465918074358/a4.xml","form_type":"4"}}]}